KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Fulgent Genetics (FLGT) Shares Repurchased (2016 - 2026)

Fulgent Genetics' Shares Repurchased history spans 8 years, with the latest figure at $40.1 million for Q1 2026.

  • On a quarterly basis, Shares Repurchased rose 361.78% to $40.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $42.3 million, a 387.19% increase, with the full-year FY2025 number at $10.9 million, up 4737.33% from a year prior.
  • Shares Repurchased hit $40.1 million in Q1 2026 for Fulgent Genetics, up from $2.2 million in the prior quarter.
  • Over the last five years, Shares Repurchased for FLGT hit a ceiling of $40.1 million in Q1 2026 and a floor of $225000.0 in Q1 2024.
  • Historically, Shares Repurchased has averaged $19.7 million across 5 years, with a median of $22.9 million in 2023.
  • Biggest five-year swings in Shares Repurchased: decreased 21.32% in 2023 and later skyrocketed 3757.33% in 2025.
  • Tracing FLGT's Shares Repurchased over 5 years: stood at $29.1 million in 2022, then decreased by 21.32% to $22.9 million in 2023, then crashed by 99.02% to $225000.0 in 2024, then soared by 880.0% to $2.2 million in 2025, then soared by 1717.6% to $40.1 million in 2026.
  • Business Quant data shows Shares Repurchased for FLGT at $40.1 million in Q1 2026, $2.2 million in Q2 2025, and $8.7 million in Q1 2025.